This systematic review and meta‐analysis protocol aims to critically evaluate the available evidence from randomized and nonrandomized clinical trials regarding the effectiveness, safety, and immunogenicity of the second COVID‐19 vaccine booster in older adults worldwide.
Abstract
Older adults remain highly vulnerable to severe COVID‐19 outcomes due to immunosenescence and comorbidities. Although booster vaccination strategies have reduced hospitalizations and mortality, evidence regarding the effectiveness, safety, and immunogenicity of a second COVID‐19 vaccine booster dose in older adults remains fragmented. This systematic review and meta‐analysis protocol aims to critically evaluate the available evidence from randomized and nonrandomized clinical trials (NRCTs) regarding the effectiveness, safety, and immunogenicity of the second COVID‐19 vaccine booster in older adults worldwide.
Importance
SARS-CoV-2 remains a substantial cause of respiratory illness, morbidity, and mortality. Evidence to date has demonstrated that COVID-19 vaccines reduce the risk of severe disease, including hospitalization and death.
Objective
This systematic review identifies and summarizes newly published studies report...
Rachel A. Lipson, Emily Senerth, Michelle A. Watson et al.· Journal of the American Medi...· 2 citations
ABSTRACT Individual studies indicate stronger and persistent long-term immunogenicity with TZ84-based than HM175-based hepatitis A vaccines. This systematic review and meta-analysis compared immunogenicity and safety of inactivated TZ84- and HM175-based hepatitis A vaccines in children and adolescents. Studies involvin...
R. Kundu, A. Ghosh, A. Toppo et al.· Human Vaccines & Immunothera...· 0 citations
Background/Objectives: The bivalent RSVpreF vaccine is effective at preventing respiratory syncytial virus (RSV)-associated lower respiratory tract illness in adults. However, data regarding safety and immunogenicity of RSVpreF in Korean populations are limited. Methods: This was a phase 3, multicenter, placebo-control...
W. Choi, Karen Quan, James Baber et al.· Vaccines· 0 citations
Background/Objectives: The efficacy and safety profiles of CYD-TDV and TAK-003 are established, but multiple publications may derive from the same randomized trial population and therefore not represent independent evidence. We evaluated efficacy, immunogenicity, and safety while distinguishing independent trials from...
J. P. Sanchez Guanilo, Carmen A. Contreras, M. Arce-Huamaní· Vaccines· 0 citations
Overall, adverse events were mild, transient, and comparable across vaccines and most included trials reported no serious adverse events (SAEs), indicating a favorable safety profile.
Muhammad Hussain, Muhammad Hassan, Abdul Hannan et al.· Frontiers in Public Health· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
